Luo Ji
Laboratory of Cancer Biology and Genomics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20814, USA.
Trends Cancer. 2016 Jun;2(6):313-324. doi: 10.1016/j.trecan.2016.05.001.
Advances in translational research are often driven by new technologies. The advent of microarrays, next-generation sequencing, proteomics and RNA interference (RNAi) have led to breakthroughs in our understanding of the mechanisms of cancer and the discovery of new cancer drug targets. The discovery of the bacterial clustered regularly interspaced palindromic repeat (CRISPR) system and its subsequent adaptation as a tool for mammalian genome engineering has opened up new avenues for functional genomics studies. This review will focus on the utility of CRISPR in the context of cancer drug target discovery.
转化医学研究的进展往往由新技术推动。微阵列、新一代测序、蛋白质组学和RNA干扰（RNAi）的出现，使我们在理解癌症机制和发现新的癌症药物靶点方面取得了突破。细菌成簇规律间隔短回文重复序列（CRISPR）系统的发现及其随后作为哺乳动物基因组工程工具的应用，为功能基因组学研究开辟了新途径。本综述将聚焦CRISPR在癌症药物靶点发现方面的应用。
